Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

View:
Post by InvrsContrarian on Jul 27, 2020 12:36pm

Aristotle

What would one pay for a cancer screener that tests for 10 cancers at once? What is fair market value for such a test. Then I beg you to run conservative testing numbers once this covid thingy had passed and then the possibility of royalty rights when they release the test to other labs. Would stage retains the rights or sell it off to Pfizer or some other conglomerate? That's the question I'm contenplating.
Comment by SAGDollar on Jul 27, 2020 12:59pm
JHT stated more than 1000 USD less than 3000 USD per each Aristotle test. Which is pretty competitive where they can make good profits but not be unaffordable. In regards to Grail their test is in R&D phase still with no clinical validation in addition to a lesser sensitivity and specificity.
Comment by Cutman on Jul 27, 2020 1:00pm
What is a realistic price? So let say the doctor suspect a cancer and wants to send you for scans and tests? You gotta know what involve a pan screening for cancer Head scan: brain tumor or mets Chest scan: lung, pancreas cancer or mets Abdo scan: liver cancer or mets, gyne cancers Spine and pelvis: bone mets or primary cancer Gastroscopy: upper GI cancer Colonoscopy: lower GI cancer Once they ...more  
Comment by InvrsContrarian on Jul 27, 2020 1:07pm
My thoughts are sitting in that price range as well. I know someone who had beaten lung cancer because it was detected by chance. Now he would be a good candidate for a flare up and he would want to get tested to find out if the cancer came back. Or if it changed into something else.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities